Bausch Health Companies Inc. BHC

What this company does

Bausch Health Companies Inc. develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter products and aesthetic medical devices, primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, and, through its approximately 88% ownership of Bausch + Lomb Corporation, branded and branded generic pharmaceuticals, OTC products and medical devices in the therapeutic areas of eye health. The Company's products are marketed directly or indirectly in approximately 90 countries. Its portfolio of products falls into five reportable segments: Salix, International, Solta Medical, Diversified and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products, with the Xifaxan product line currently representing approximately 85% of Salix segment revenues. The International segment consists of sales, other than sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. The Diversified segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.

Written from the business description in Bausch Health Companies Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.